替吉奥胶囊联合伊立替康治疗晚期结直肠癌的临床观察

目的评价替吉奥胶囊联合伊立替康治疗晚期结直肠癌的临床疗效及不良反应。方法选择晚期结直肠癌一线治疗失败并有可评价病灶的患者54例,予以IRIS方案(伊立替康,替吉奥)化疗。评价客观疗效,并观察不良反应;观察治疗前后患者生存质量、外周血中自然杀伤(NK)细胞及T细胞亚群变化、外周血中血管内皮生长因子(VEGF)水平。结果全部54例患者均可评价疗效,有效率(RR)20.1%,疾病控制率(DCR)59.3%,疾病进展时间(TTP)为4.8月。不良反应主要是中性粒细胞减少、腹泻及胆碱能综合征,无毒性相关死亡病例。54例患者治疗后生存质量改善率为87.0%;治疗后NK细胞活性提高、CD4+/CD8+提高、血清VEGF水平降低。结论替吉奥胶囊联合伊立替康治疗晚期结直肠癌疗效较好,不良反应患者可耐受,可进一步研究推广。

Clinical observation on gimeracil and oteracil porassium capsules combined with irinotecan for advanced colorectal cancer

Objective To evaluate the clinical effects and adverse reactions of gimeracil and oteracil porassium capsules combined with irinotecan in the treatment of advanced colorectal cancer.Methods Fifty-four patients failing in the first-line therapy of advanced colorectal cancer and having assessable focus were selected and administered ISIR(irinotecan,S-1) chemotherapy.The objective efficiency was evaluated,and adverse reactions were observed.The quality of life,changes of natural killer(NK) cells and T cell subgroups in peripheral blood as well as the level of vascular endothelial growth factor(VEGF) in peripheral blood were observed before and after treatment.Results All of the 54 patients could be assessed in the study,in which the response rate(RR) and disease control rate(DCR) were 20.1% and 59.3%,respectively,and time to progression(TTP) was 4.8 months.Adverse reactions mainly included neutropenia,diarrhea and cholinergic syndrome,and there was no toxicity-related dead case.After treatment,the improved rate of quality of life among 54 patients was 87.0%.NK cell viability and CD4+/CD8+ increased,whereas the level of VEGF decreased.Conclusion Oteracil porassium capsules combined with irinotecan has better therapeutic effects in the treatment of advanced colorectal cancer,and patients with adverse reactions can be tolerable,so this regimen can be further researched and popularized.